Xinchang County Peoples Hospital

Xinchang’ao, China

Xinchang County Peoples Hospital

Xinchang’ao, China
SEARCH FILTERS
Time filter
Source Type

Dong Y.,Xinchang County Peoples Hospital | Liang G.,Xinchang County Peoples Hospital | Yuan B.,Xinchang County Peoples Hospital | Yang C.,Shanghai University | And 2 more authors.
Tumor Biology | Year: 2015

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), one of the first found cancer-associated long noncoding RNAs (lncRNAs), involves in the development and progression of many types of tumors. An aberrant expression of MALAT1 was observed in hepatocellular carcinoma, cervical cancer, breast cancer, ovarian cancer, and colorectal cancer. However, the exact effects and molecular mechanisms of MALAT1 in osteosarcoma progression are still unknown up to now. Here, we investigated the role of MALAT1 in human osteosarcoma cell lines and clinical tumor samples in order to determine the function of this molecule. In our research, the MALAT1 messenger RNA (mRNA) was highly expressed in human osteosarcoma tissues, and its expression level was closely correlated with pulmonary metastasis. Then, we employed lentivirus-mediated knockdown of MALAT1 in U-2 OS and SaO2 to determine the role of MALAT1 in osteosarcoma cell lines. Lentivirus-mediated MALAT1 small interfering RNA (siRNA) could efficiently downregulated the expression level of MALAT1 in osteosarcoma cell lines. Knockdown of MALAT1 inhibited the proliferation and invasion of human osteosarcoma cell and suppressed its metastasis in vitro and vivo. At the same time, the proliferating cell nuclear antigen (PCNA), matrix metallopeptidase 9 (MMP-9), phosphorylated PI3Kp85α, and Akt expressions were significantly inhibited in MALAT1-deleted cells. These findings indicated that MALAT1 might suppress the tumor growth and metastasis via PI3K/AKT signaling pathway. Taken together, our data indicated that MALAT1 might be an oncogenic lncRNA that promoted proliferation and metastasis of osteosarcoma and could be regarded as a therapeutic target in human osteosarcoma. © 2014, International Society of Oncology and BioMarkers (ISOBM).


Zhao B.-B.,Shanghai JiaoTong University | Zhao B.-B.,Xinchang County Peoples Hospital | Wang Y.,Shanghai JiaoTong University | Mi J.-Q.,Shanghai JiaoTong University | And 5 more authors.
Journal of Shanghai Jiaotong University (Medical Science) | Year: 2011

Objective: To evaluate the curative effect of Bortezomib based chemotherapy in treatment of patients with newly diagnosed multiple myeloma, and explore the prognositic factors. Methods: Thirty-eight patients with newly diagnosed multiple myeloma received Bortezomib based chemotherapy, and the drugs used in chemotherapy included Melphalan + Prednisone, Dexamethasone, Dexmethasone + Cyclophosphamide or Dexamethasone + Adriamycin. Each course of treatment lasted for 3 to 4 weeks, and intravenous injection of 1.3 mg/m 2 Bortezomib was performed on the 1st, 4th, 8th and 11th day of each course. Patients were managed with 2 to 10 courses. Response to Bortezommib was assessed according to the criteria of European Croup for Blood and Marrow Transplantation, and adverse events were evaluated according to the criteria of National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0. The prognosis factors were analysed by Logrank test and COX regression model. Results: The median duration of follow-up was 19 months. The overall response rate (complete remission + very good partial remission + partial remission) was 86.84%. The median progression-free survival was 19.47 months, and the median overall survival was 39.17 months. Univariate analysis and multivariate analysis revealed that complete remission and very good partial remission after treatment were prognostic factors, while M protein typing, age, Durie-salmon staging, high serum creatinine, low hemoglobin, low albumin, high β 2 microglobulin and high lactate dehydrogenase were not related to prognosis. The major adverse events during treatment were gastrointestinal sympotoms, leukocytopenia, thromhocytopenia, peripheral neuropathy and fatigue. Conclusion: Bortezomib based chemotherapy is well tolerated and effective in treatment of patients with newly diagnosed multiple myeloma, which overcomes the poor prognosis conferred by traditional prognosis factors.


Zhang X.-D.,Xinchang County Peoples Hospital | Fang J.,Xinchang County Peoples Hospital | Lu H.,Xinchang County Peoples Hospital | Liu F.,Xinchang County Peoples Hospital
International Eye Science | Year: 2014

AIM: To retrospectively evaluate the effect of lens extraction combined with vitrectomy to treat traumatic lens dislocation with secondary glaucoma.METHODS: Thirty-one eyes (31 cases) of lens dislocation caused by blunt trauma with secondary glaucoma were treated respectively with cataract extraction combined with anterior vitrectomy, trabeculectomy and intraocular lens implantation. The visual acuity and pressure were observed 1wk, 1 and 3mo after operative.RESULTS: Thirty-one eyes were all complete the operation successfully, and 6 eyes were given combined trabeculectomy, 9 eyes were implanted anterior chamber intraocular lens implantation (IOL) and 15 eyes were given posterior chamber suture fixation. Sixteen eyes were implanted in one-stage operation, while 8 eyes were implanted in two-stage operation. All intraocular pressure (IOP) were controlled to the normal level after operation and 23 eyes had visual acuity of more than 0.3.CONCLUSION: Lens extraction combined with vitrectomy is an effective method for treatment of lens dislocation with secondary glaucoma. In order to control the IOP and get well visual function, we should choose IOL implantation or trabeculectomy according to the patient's condition.


PubMed | Xinchang County Peoples Hospital
Type: Journal Article | Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine | Year: 2015

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), one of the first found cancer-associated long noncoding RNAs (lncRNAs), involves in the development and progression of many types of tumors. An aberrant expression of MALAT1 was observed in hepatocellular carcinoma, cervical cancer, breast cancer, ovarian cancer, and colorectal cancer. However, the exact effects and molecular mechanisms of MALAT1 in osteosarcoma progression are still unknown up to now. Here, we investigated the role of MALAT1 in human osteosarcoma cell lines and clinical tumor samples in order to determine the function of this molecule. In our research, the MALAT1 messenger RNA (mRNA) was highly expressed in human osteosarcoma tissues, and its expression level was closely correlated with pulmonary metastasis. Then, we employed lentivirus-mediated knockdown of MALAT1 in U-2 OS and SaO2 to determine the role of MALAT1 in osteosarcoma cell lines. Lentivirus-mediated MALAT1 small interfering RNA (siRNA) could efficiently downregulated the expression level of MALAT1 in osteosarcoma cell lines. Knockdown of MALAT1 inhibited the proliferation and invasion of human osteosarcoma cell and suppressed its metastasis in vitro and vivo. At the same time, the proliferating cell nuclear antigen (PCNA), matrix metallopeptidase 9 (MMP-9), phosphorylated PI3Kp85, and Akt expressions were significantly inhibited in MALAT1-deleted cells. These findings indicated that MALAT1 might suppress the tumor growth and metastasis via PI3K/AKT signaling pathway. Taken together, our data indicated that MALAT1 might be an oncogenic lncRNA that promoted proliferation and metastasis of osteosarcoma and could be regarded as a therapeutic target in human osteosarcoma.

Loading Xinchang County Peoples Hospital collaborators
Loading Xinchang County Peoples Hospital collaborators